Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
For many years, ovarian cancer was called the “silent killer” because people thought it caused no symptoms until it was too late to treat. Recent research has shown this is not true. Most women with ovarian cancer do have symptoms in the months before diagnosis. The problem is that these symptoms are often mild and can be mistaken for common stomach or urinary issues, so they are easy to overlook.
The symptom profile is often described as “whispering” rather than “silent.” These whispers typically manifest as the “BEAT” constellation: Bloating that is persistent and does not resolve; Eating difficulties, such as feeling full quickly (early satiety) or lack of appetite; Abdominal or pelvic pain; and Trouble with urination, including urgency or frequency. Unlike the fluctuating bloating associated with menstrual cycles or dietary indiscretions, ovarian cancer-associated bloating is constant and progressive.
It is important to notice if these symptoms are new, happen often, or last a long time. If a woman has these symptoms more than twelve times in a month, or if they are different from what is normal for her, she should see a doctor. Calling ovarian cancer “subacute” instead of “silent” encourages women to speak up and get checked when they notice ongoing changes in their bodies.
As the disease progresses into the peritoneal cavity, the physiological mechanisms driving symptoms become more overt. The accumulation of ascites—fluid in the abdomen—is a major driver of physical distress. Patients may notice an increase in abdominal girth or waist size, often requiring a change in clothing size, even while losing weight elsewhere (muscle wasting). This paradoxical weight change is a red flag. The fluid pushes up against the diaphragm, causing shortness of breath (dyspnea) even with minimal exertion.
The “mass effect” refers to the physical pressure exerted by the tumor implants on surrounding organs. Implants on the bladder surface reduce its capacity, leading to increased urinary frequency. Nodules on the rectum or sigmoid colon can cause constipation or a sense of incomplete bowel evacuation. In more severe cases, the bowel can become narrowed or kinked by the cancer, leading to nausea, vomiting, and sub-acute bowel obstruction.
Fatigue is another pervasive symptom, driven by the tumor’s metabolic demands and the systemic inflammatory response it provokes. This is not essentially simple tiredness but a profound exhaustion that does not improve with rest. Additionally, some women may experience dyspareunia (pain during intercourse) or abnormal vaginal bleeding, although these are less common than the gastrointestinal presentations.
Genetics plays a more substantial role in ovarian cancer than in almost any other common solid tumor. Approximately twenty to twenty-five percent of ovarian cancers are hereditary, driven by germline mutations passed down through families. The most well-known are mutations in the BRCA1 and BRCA2 genes. These genes are responsible for repairing double-strand DNA breaks via homologous recombination. When these genes are mutated, the DNA repair mechanism is defective, leading to a high accumulation of genetic errors and a dramatically increased risk of breast and ovarian cancer.
Carriers of BRCA1 mutations have a lifetime risk of developing ovarian cancer of approximately forty to sixty percent, while BRCA2 carriers have a risk of ten to thirty percent. These cancers tend to grow at a younger age than sporadic cases. Beyond BRCA, Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer) is another major contributor. Lynch Syndrome is caused by defects in mismatch repair genes (MLH1, MSH2, MSH6, PMS2) and is primarily associated with colon and endometrial cancers, but also carries a significantly elevated risk for ovarian cancer, typically of the endometrioid or clear cell subtypes.
Other genes in the homologous recombination pathway, such as RAD51C, RAD51D, and BRIP1, have also been identified as moderate-risk genes. The identification of these mutations is not only crucial for the patient’s treatment (determining eligibility for PARP inhibitors) but also for “cascade testing” of family members, allowing relatives to undergo preventive surgeries, such as salpingo-oophorectomy, before cancer develops.
The “incessant ovulation” hypothesis is one of the leading theories explaining sporadic ovarian cancer risk. This theory posits that the physical act of ovulation—the bursting of the ovarian follicle to release an egg—causes trauma to the ovarian surface epithelium. This trauma requires repeated cell division for repair. The more times a woman ovulates in her lifetime, the higher the chance of a genetic error occurring during this repair process.
This hypothesis explains why factors that suppress ovulation are protective. Women who have used oral contraceptives (birth control pills) for five years or more reduce their risk of ovarian cancer by approximately fifty percent. This protection persists for decades after stopping the medication. Similarly, pregnancy and breastfeeding, which are periods of anovulation, are associated with a reduced risk. Conversely, nulliparity (never having given birth) or early menarche and late menopause (a long reproductive window) are associated with a higher risk.
Infertility itself is a complex risk factor. While infertility is associated with a slightly higher risk, it is difficult to disentangle whether the risk comes from the underlying cause of infertility (such as endometriosis) or the condition itself. Current data suggest that the use of fertility drugs does not significantly increase the risk of invasive ovarian cancer, although monitoring is ongoing.
Endometriosis is a chronic condition in which tissue similar to the lining of the uterus grows outside the uterus, often on the ovaries and the peritoneum. It is a state of chronic inflammation and hormonal dysregulation. There is a well-established link between endometriosis and specific subtypes of ovarian cancer, namely clear cell carcinoma and endometrioid carcinoma. These are collectively termed “endometriosis-associated ovarian cancers.”
The mechanism involves the transformation of the ectopic endometrial tissue on the ovary. The iron present in the old blood within endometriotic cysts (chocolate cysts) induces oxidative stress, leading to DNA damage and promoting mutations in genes such as ARID1A and PIK3CA. While the absolute risk of an individual with endometriosis developing cancer is low, the relative risk is elevated compared to the general population.
Pelvic Inflammatory Disease (PID), a severe infection of the reproductive organs usually caused by sexually transmitted bacteria, is another inflammatory risk factor. The chronic inflammation and scarring associated with PID may create a microenvironment conducive to carcinogenic changes. Conversely, tubal ligation (having “tubes tied”) is a protective factor. This may be because it prevents carcinogens (like talc or infectious agents) from traveling up the reproductive tract to the ovaries, or because the procedure disrupts the blood supply to the fimbriae, reducing their function.
Send us all your questions or requests, and our expert team will assist you.
This symptom, known as early satiety, occurs because the cancer often causes a buildup of fluid (ascites) in the abdomen or large tumor masses on the omentum. This fluid and tissue take up space in the abdominal cavity and press against the stomach, preventing it from expanding, usually when you eat, leading to a feeling of fullness after only a few bites.
This has been a subject of intense debate and legal action. Some studies suggest a minimal increase in risk with the long-term use of talcum powder in the genital area, possibly due to inflammation or potential asbestos contamination in older talc products. However, the scientific evidence is mixed and not definitive. Major health organizations classify it as a “possible” carcinogen.
Yes. Breast and ovarian cancer are often linked genetically, most commonly through mutations in the BRCA1 and BRCA2 genes. If your family has a strong history of breast cancer, particularly at young ages, in both breasts, or in male relatives, it may indicate a hereditary syndrome that also increases the risk of ovarian cancer.
Long-term use of hormone replacement therapy after menopause, particularly estrogen-only treatment, has been linked to a slightly increased risk of ovarian cancer. The risk appears to diminish after the treatment is stopped. The decision to use HRT involves weighing this small potential risk against the benefits for bone and heart health and symptom relief.
Cancer is fundamentally a disease of accumulating genetic damage. As we age, our cells have divided more times, accumulating more errors in their DNA, and our body’s repair mechanisms become less efficient. For ovarian cancer, the peak incidence is in the sixties, reflecting the cumulative effect of decades of ovulation and environmental exposures.
Many people are surprised to learn that lower back pain can signal ovarian cancer. This is true if the pain is new, keeps coming back,
Abdominal bloating and a visibly larger stomach are common signs of ovarian cancer. These symptoms are often mistaken for regular digestive issues. At Liv Hospital,
Many people think that ovarian cancer always leads to vaginal bleeding. But, the truth is more nuanced. We’re here to tell you that bleeding isn’t
Many women feel like they need to go to the bathroom all the time. But, it’s often because of ovarian cysts. These growths can make
Ovarian cancer is often called a ‘silent killer’ because its symptoms are not obvious and it’s often diagnosed late. Early detection is key to better
Ovarian cancer is a major threat to women’s health. Some groups face much higher risks because of their genes, family history, and lifestyle. It’s key
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
